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Abstract
Background: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and
AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly
inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood
and prediction of IRIS is not possible.
Methods and Findings: We prospectively followed 101 ART-naı ¨ve Ugandans with AIDS and recent CM for one year after
initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not
develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS)
manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21%
without IRIS. CM-IRIS was independently associated with death (HR=2.3, 95% CI 1.1–5.1, p=0.04). Patients experiencing
subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p=0.006). Higher pre-ART
levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-a, granulocyte colony-stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted
future IRIS in multivariate analyses (area under the curve [AUC]=0.82). An algorithm based on seven pre-ART serum
biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART
was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with
increasing hazard of IRIS by time-to-event analysis (each p#0.001). At the time of IRIS onset, multiple proinflammatory
cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing
GM-CSF, and CRP level .32 mg/l (highest quartile). Pre-ART CRP level .32 mg/l alone was associated with future death
(OR=8.3, 95% CI 2.7–25.6, p,0.001).
Conclusions: Pre-ART increases in Th17 and Th2 responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses
(e.g., TNF-a, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction
and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the
risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions.
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Cryptococcal meningitis (CM), caused by the fungal organism
Cryptococcus neoformans (commonly termed simply ‘‘cryptococcus’’) is
the most common fatal central nervous system (CNS) infection in
persons with AIDS and is the initial AIDS-defining illness in 20%–
30% of AIDS patients in Africa, causing 20%–40% of AIDS-
attributable mortality [1–4]. The US Centers for Disease Control
(CDC) estimates approximately 1 million CM cases occur
annually, with 70% in sub-Saharan Africa [5]. The incidence of
CM among Ugandans with CD4 counts ,200 cells/ml is 10%
annually without antiretroviral therapy (ART) [1], and without
ART, almost all persons with CM die within 6 mo [6]. Although
ART availability has led to improved CM survival in Africa [7–9],
mortality after CM is still high, in part due to paradoxical HIV
immune reconstitution inflammatory syndrome (IRIS), an exag-
gerated inflammatory response causing a subset of persons with
recent CM to paradoxically deteriorate on ART in the presence of
improving immune function [10–14]. Paradoxical CM-IRIS
incidence has been reported as 10%–42% among ART-naı ¨ve
persons with CM, with a pooled average of 18% (95% CI 14%–
23%) [7,14–17]. CM-IRIS is of grave concern because of its high
incidence and mortality (33%–66%) [7,14,17,18]. In many
resource-limited regions, particularly sub-Saharan Africa where
CM is the second most common AIDS-defining opportunistic
infection [1–4], CM-IRIS is a major clinical problem.
The pathophysiology of paradoxical IRIS is largely unknown,
but IRIS is hypothesized to be due to dysregulated reconstitution
of antigen-specific immunity, leading to an exaggerated immune
response to persisting antigens despite microbiologic treatment
success [19–22]. The antigens, which may be present as intact
organisms, dead organisms, or debris [23], evoke pathological
inflammatory responses that cause paradoxical clinical deteriora-
tion [24–26].
A healthy immune response in non-immunocompromised hosts
to cryptococcal infection depends on coordinated interactions
between antigen-presenting cells (APCs) and effector T cells,
thereby generating an effective type-1 helper T cell (Th1) immune
response that clears the infection. Interferon-gamma (IFN-c)
induces classical activation of macrophages to destroy phagocy-
tosed cryptococcus (Figure 1) [27–30]. In contrast, Th2 responses
are not protective and allow intracellular proliferation of
cryptococcus within macrophages, resulting in disseminated
infection [31,32]. Colony-stimulating factors, such as granulocyte
colony-stimulating factor (G-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF), also up-regulate anti-crypto-
coccal activity of the innate immune system [33–36]. We
hypothesize that an ineffectual immune response to cryptococcus
occurs in a subset of AIDS patients, and these abnormal responses
predispose to the development of IRIS.
We prospectively studied the incidence, clinical presentations,
outcomes, and cytokine profiles of CM-IRIS in a cohort of HIV-
infected Ugandans initiating ART in order to identify serum
biomarkers of inflammation that can be used to predict and
diagnose CM-IRIS. Characterizing the abnormal inflammatory
responses associated with IRIS will enable the future selection of
rational IRIS treatment strategies targeting specific inflammatory
pathways.
Methods
Participants
One hundred two ART-naı ¨ve patients with AIDS and recent
CM were enrolled for 12 mo of longitudinal evaluation after ART
initiation. One participant was lost to follow up at ,2w ka n d
excluded. Participants with CM were enrolled from May 2006
through September 2009 at Mulago Hospital in Kampala, Uganda
[7]. Patients were treated with 0.7–1.0 mg/kg/day of amphotericin
for 14 doses, then fluconazole 400 mg daily, and subsequently
started on ART as outpatients at the Infectious Disease Institute
clinic. ART was initiated at a median of 34 d (interquartile range
[IQR] 24–41 d) after CM diagnosis and consisted of: zidovudine,
lamivudine, and efavirenz or stavudine, lamivudine, and nevir-
apine. After ART initiation, participants attended clinic visits
biweekly for 3 mo then monthly through 12 mo. Evaluation for
IRIS was performed at each scheduled visit and when participants
presented acutely. When IRIS was suspected, alternative diagnoses
were evaluated by history, examination, laboratory, lumbar
puncture, and/or radiological investigations. The International
Network for the Study of HIV-associated IRIS (INSHI) consensus
working case definition for CM-IRIS was used [37]. Suspected but
unconfirmed IRIS events were considered non-IRIS. Each
participant provided written informed consent for protocols
approved by the institutional review boards at the University of
Minnesota, Makerere University, and Uganda National Council for
Science and Technology.
Figure 1. Normal Immunology of Cryptococcosis. Left: Myeloid dendritic cells serve as APCs that recognize and phagocytose C. neoformans
and generate cytokine signals of IL-1b, IL-6, and TNF-a. GXM polysaccharide capsule (i.e. CRAG) activates APCs via Toll-like receptor 4 and CD14.
Center: Activated dendritic cells migrate to lymphatic tissue and present cryptococcal mannoprotein antigen to naı ¨ve T cells via MHC-II receptors.
This coupled with CD28 costimulation results in Th1 differentiation. Right: Antigen-specific Th1 T cell recognition results in IFN-c secretion causing
classical activation of macrophages with up-regulation of reactive oxygen species (ROS) production; IL-6, TNF-a, IL-8 (CXCL8), CXCL10, fibroblast
growth factor (FGF)-2 secretion by macrophages. T cells also secrete additional inflammatory mediators of GM-CSF and VEGF. Th2 T cell responses are
not protective. Macrophages also release G-CSF which up-regulates leukotriene synthesis and anticryptococcal activity of neutrophils.
doi:10.1371/journal.pmed.1000384.g001
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CD4
+ T cell and plasma HIV RNA measurements were made
every 12 wk and at suspected IRIS events. From 2007 onward,
CD4
+ T cells were also measured at 4 and 8 wk of ART. Serum
was frozen at 280uC at visits (0, 2, 4, 8, 12, 24 wk and suspected
IRIS events). We measured 27 serum cytokines/chemokines in
duplicate (Human 27-Plex Panel, Bio-Rad, Hercules, California)
according to manufacturer protocol via a Luminex 100 system
(Austin, Texas). Plasma D-dimer was measured in 1:25 dilution by
IMUCLONE D-Dimer ELISA (America Diagnostics, Stamford,
Connecticut). Serum C-reactive protein (CRP) was measured by
reflectance spectrophotometry at the University of Minnesota
clinical laboratory. Baseline specimens, collected on the day of
ART initiation, were missing from nine patients. Serum
cryptococcal antigen (CRAG) titers were batched with each
patient’s specimens being tested simultaneously in parallel
(Immuno-Mycologics, Norman, Oklahoma). At the time of CM-
IRIS onset, cerebrospinal fluid (CSF) analysis excluded alternative
diagnoses. Investigations included: Gram and acid-fast bacilli
(AFB) stains, bacterial and fungal cultures, 16S ribosomal DNA
amplification for bacteria [38], and viral culture in Vero cells and
RT-PCR amplification for arboviruses performed at the Centers
for Disease Control–Fort Collins, Colorado. Patients presenting
with pneumonitis were offered bronchoalveolar lavage with
separate consent. Histopathology or autopsy specimens always
included AFB staining to exclude tuberculosis (TB).
Statistical Analysis
The primary comparison was between CM patients developing
IRIS and control CM patients without IRIS. Non-normally
distributed variables (e.g., cytokines, CD4) were tested at baseline
by Mann-Whitney U and presented as median with IQR. p-Values
are two-sided with a,0.05 (SPSS 18.0.1, Chicago, IL). Cytokine
p-values were adjusted for multiple comparisons via Benjamini-
Hochberg methods [39]. To determine the risk of future CM-
IRIS, pre-ART demographic variables, standard HIV parameters,
and log2-transformed cytokines were analyzed. A training model
was developed in October 2008 after the first 65 participants were
enrolled [40], which narrowed the selection from all 29 possible
biomarkers to consideration of: CRP, interleukin (IL)-4, IL-8, IL-
12, IL-17, G-CSF, GM-CSF, CCL2 (MCP-1), tumor necrosis
factor (TNF)-a, and vascular endothelial growth factor (VEGF).
To evaluate the additive predictive power of the above cytokine
set, we fitted penalized logistic regression models with penalty
parameters specified by the Lasso method [41]. Cross-validation
was used to estimate the penalty parameters in the model, with
10% of the data removed for each subset estimate. Models were
fitted using the ‘‘penalized’’ package in R [42]. The unadjusted
models look at the serum biomarkers alone. Six participants were a
priori excluded during model development (four suspected IRIS,
two TB-IRIS). We also considered an adjusted model including
CD4 and the time from CM to ART initiation as unpenalized
regression coefficients.
To describe the degree of inflammation occurring at CM-IRIS
events, two methods were used. First, cytokine profiles at IRIS
events were compared with CM controls time-matched from 4–
12 wk of ART (corresponding to the approximate IQR of IRIS
timing). Second, we modeled the longitudinal within-patient
cytokine changes by Cox regression with a time-dependent
covariate to represent each cytokine profile and the profile’s
evolution over time on ART [43,44]. The outcome variable in the
Cox model was the time to first IRIS event. The ‘‘survival
package’’ in R fitted the model on log2-transformed data [42].
Sandwich estimates determined the variance of regression
coefficients, and the relative IRIS risk was portrayed as the
hazard ratio (HR). The p-values resulting from each cytokine test
were adjusted for multiple comparisons [39]. The Cox model
allowed the use of the full longitudinal cytokine profile in order to
test for association with the hazard of CM-IRIS events. The HR
measures the relative risk of CM-IRIS for each two-fold change in
the cytokine expression at any given time point through the first
6 mo of ART.
Results
Clinical Features of Cryptococcal IRIS
In this cohort, 57 paradoxical IRIS events occurred in 45
persons (45%; 95% CI 35%–55%; see Figure S1), of whom 35
persons had one event, nine persons had two events, and one
person had three events. The median pre-ART CD4 count was 19
(IQR 7–38) cells/ml. Baseline demographic features and both
virologic and CD4
+ T cell responses to ART were similar in
patients who did and did not develop cryptococcal IRIS (Table 1).
The most frequent clinical manifestation of paradoxical crypto-
coccal IRIS was aseptic meningitis, which occurred in 30% (30/
101) after appropriate clinical responses to initial amphotericin
therapy. In these 30 patients, CM-IRIS manifested as headache
(87%), photophobia (33%), vomiting (30%), meningismus (27%),
papilledema (27%) and seizures (20%). Analysis of CSF showed
elevated WBCs in 75% (median 50, range 5–200/ml, lymphocytic
predominance), elevated protein in 88% (median 80, range 40–
150 mg/dl), and sterile cultures in 96% (27/28, missing two). Each
variable was increased compared with pre-ART values (p,0.001).
Six patients with CM-IRIS presented with seizures that were
accompanied by cryptococcoma(s) on CT and/or postmortem
exam; three of these patients had concomitant aseptic meningitis.
Other paradoxical cryptococcal IRIS events included: pneumoni-
tis with nonproductive cough and radiologic infiltrate (n=14),
CNS cryptococcoma without meningitis (n=3), sepsis syndrome
with sterile cultures (n=2), and single episodes each of marked
lymphadenopathy, retinitis, optic neuritis, and phlyctenular
keratoconjunctivitis. CM-IRIS events are summarized and
additional clinical details are provided in Text S1. Overall, our
results suggest that IRIS occurs in a large percentage of AIDS
patients with CM who start ART, and the manifestations of IRIS
can be severe, often involving aseptic meningitis and other CNS
manifestations.
Association between IRIS and Death
In the absence of ART, CM in Africa is associated with high
mortality [6,45]. We analyzed mortality data in our cohort to
determine whether the development of IRIS was associated with
increased mortality. Overall, 28 of 101 CM patients died (27%)
after initiating ART. Mortality was 36% (16/45) in patients with
IRIS and 21% (12/56) in those without IRIS (Figure 2). Causes of
death were cryptococcal IRIS (n=16), virologic failure and CM
relapse (n=1), paradoxical TB-IRIS (n=1), aspiration after AZT-
induced severe anemia and lactic acidosis (non-IRIS) (n=1), renal
failure (n=1), cerebrovascular event (n=1), suspected but
unverified cases of CM-IRIS (n=4), suspected pulmonary emboli
(n=2), and one unknown cause of death occurring at home. By
time-to-event analysis, mortality was higher among those experi-
encing cryptococcal IRIS (HR=2.3, 95% CI 1.1–5.1, p=0.04)
than the remainder of the cohort, alone or after adjustment for
baseline CD4 (p=0.11 for CD4). Our findings suggest that the
development of IRIS is associated with an increased risk for death
in patients with recent CM.
Biomarkers of Cryptococcal IRIS
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We sought to determine the risks for IRIS by analyzing
demographic and standard HIV parameters. For participants with
recent CM, we identified no statistically significant difference
among those who did or did not develop IRIS in baseline number
or change in CD4
+ T cell number, in baseline plasma HIV RNA,
nor in virologic suppression at 12, 24, 36, or 48 wk (Table1). CD4
recovery is displayed in Figure S2. The lack of differences in these
variables pertained to univariate or multivariate analyses,
controlling for CRP, body mass index (BMI), cytokine profiles,
as well as time-to-event analysis or comparison of quartiles. Thus,
the degree of immunosuppression, rate of immune recovery after
ART, level of viremia, and degree of viral suppression on ART
were not predictors of CM-IRIS in this prospective cohort with
very severe immunosuppression.
Median serum CRAG titers when starting ART were 4-fold
higher in participants with IRIS (1:512 cases versus 1:128 controls,
p=0.006). This result is in marked contrast to our previous CSF
report from 85 members of this cohort, in whom there were no
differences in CSF CRAG titer at time of their initial CM
diagnosis between IRIS cases and controls (median CRAG 1:1024
for both groups) [46]. A pre-ART serum CRAG $1:512 was
associated with later CM-IRIS (OR=4.2, 95% CI 1.7–10.3;
p=0.002). Though serum was not available for direct comparison
at time of their initial CM diagnosis, the implication is that patients
with IRIS likely had poorer antigen clearance in the 5-wk median
interval between CM diagnosis and ART initiation.
A concern among many clinicians is that early initiation of ART
in patients with CM could lead to an increased incidence of IRIS
and increased mortality [47]. We identified no statistical significant
difference in the incidence of IRIS in those initiating ART 11–28
d from CM-diagnosis compared with those who waited $28 d,
(44% versus 55% respectively; p=0.4) nor a statistical difference in
survival (p=0.9). Thus, earlier initiation of ART following the
diagnosis of CM was not a risk factor for IRIS.
Predictive IRIS Model
Based on a training set derived from pilot data through 2008
[40], we considered nine possible biomarkers to incorporate into a
predictive IRIS model. We used penalized logistic regression with
penalties defined by the lasso method to develop a classification
model with the best overall fit. Applying this model to our cohort,
we were able to stratify persons into high-, moderate-, and low-
risks groups with IRIS incidences of 82%, 47%, and 22%,
respectively (Figure 3), based on seven serum biomarkers collected
on the day of ART initiation (IL-4, IL-17, G-CSF, GM-CSF,
CCL2 [MCP-1], TNF-a, and VEGF). The predictive perfor-
mance (i.e. C-statistic) as quantified by the area under the curve
(AUC) of a receiver operating characteristic (ROC) curve is 0.82
for correct prediction (p,0.001).
The predictive model had better predictive performance than
CRP (AUC=0.58, p=0.25) or CRAG titer (AUC=0.67,
p=0.004). We considered an adjusted model including the pre-
ART CD4 count and the delay from CM to ART initiation.
Table 1. Demographic and laboratory parameters in comparison to occurrence of IRIS events.
Parameter Cryptococcal Meningitis p-Value
No IRIS Paradoxical IRIS Event
n 56 45
BMI 19.462.8 20.564.6 0.4
Time from CM to ART initiation, d 37618 36623
Median time (IQR) 33 (24–42) 29 (25–41) 0.4
New opportunistic infections 4 3
Paradoxical IRIS events
a —5 7
Death 9
b 17 0.04
Baseline CD4
+, cells/ml3 4 639 26626 0.26
Baseline CD8
+, cells/ml6 1 6 6347 5896684 0.8
Baseline CD4:CD8 ratio 0.06060.059 0.06360.073 0.16
Baseline eosinophils, eosinophils/ml3 0 7 6324 2336270 0.33
Eosinophils, % 13.5%67.7% 11.3%66.0% 0.20
Baseline plasma HIV RNA, log copies/ml 5.160.6 5.260.7 0.9
12 week CD4
+ T cells/ml9 8 677 92676 0.8
24 week CD4
+ T cells/ml1 0 1 658 105675 0.9
48 week CD4
+ T cells/ml1 3 0 674 175699 0.056
12 week HIV ,400 copies/ml 66% 70% 0.8
24 week ,400 copies/ml 88% 90% 0.9
Pre-ART serum CRAG titer,
median (IQR) (n=83)
1:128
(1:64 to 1:512)
1:512
(1:128 to 1:1024)
0.006
Data are expressed as mean 6 standard deviation. p-Values are via Mann-Whitney U for continuous variables and Fisher’s exact test for categorical variables. CRAG is
tested by the two independent sample median test.
aSome patients had .1 event, thus the number of events is more than the total listed as the N for the group.
bNon-IRIS deaths include: four suspected IRIS events. Two deaths are excluded in persons with virologic suppression with suspected clinical IRIS who refused LPs, with
one of these deaths attributed to suicide.
doi:10.1371/journal.pmed.1000384.t001
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considered the effect on predictive performance by using a more
parsimonious model with fewer predictors (Figure S3). The AUC
decreased in a linear fashion with inclusion of fewer predictors,
such that the AUC was 0.72 for a four-variable model of IL-17,
GM-CSF, TNF-a, and VEGF. Although these biomarkers are
associated with prediction of IRIS, these factors alone or in
aggregate may not be causative of IRIS. However, the roles of
these cytokines in immune responses to cryptococcus (Figure 1)
suggest that these cytokines may play a role in IRIS pathogenesis.
Overall, our results suggest that the risk of IRIS could be stratified
on the basis of pre-ART biomarker levels in persons with
cryptococcosis.
Biomarkers Associated with Cryptococcal IRIS
Since predictive models have a different goal and interpretation
than do models of association, we also tested for association. We
considered the seven biomarkers identified above in a multivariate
logistic model to determine their statistical association with IRIS
(Table 2). In a multivariate model, future CM-IRIS was associated
with increased pre-ART levels of CRP, IL-4, and IL-17 (each
p,0.05). Since Th1, rather than Th2 responses, are protective in
cryptococcosis [28], a Th2 response to cryptococcus characterized
by increased IL-4 production by T cells might be associated with
ineffective antigen clearance, leading to a predisposition to the
subsequent development of IRIS. Notably, increased pre-ART
levels of IL-17, often viewed as a proinflammatory cytokine, were
also associated with future IRIS. Moreover, pre-ART levels of the
inflammatory marker CRP were increased among patients who
subsequently developed IRIS (mean 2.3-fold higher, 95% CI 1.2–
3.5, p=0.03). Persons with CRP .32 mg/l levels (highest
quartile) experienced IRIS with an increased incidence of 74%
(OR=3.9, 95% CI 1.3-11.3, p=0.01) and shorter time-to-event
(HR=3.4, 95% CI 1.8–6.6, p,0.001) compared with persons
with CRP,32 mg/l, independent of CD4+ count. Our data
suggest that not only is the presence of pre-ART inflammation
associated with risk for IRIS, but the type of inflammation is
important, with the closest association of IL-4 (Th2) and IL-17
(Th17) responses with a predisposition toward CM-IRIS
development.
Although high pre-ART levels of IL-4, IL-17, and CRP were
associated with increased risk of IRIS, lower pre-ART levels of
VEGF, G-CSF, and TNF-a were also associated with increased
risk (p,0.05 each). IRIS developed in 79% (11/14) of patients
with undetectable serum levels of TNF-a when starting ART, but
only 35% (27/78) with detectable TNF-a (OR=4.9, 95% CI 1.3
to 19.0, p=0.019). TNF-a is involved in innate immunity by
activating phagocytosis of cryptococcus by macrophages, antigen
processing, and proinflammatory recruitment of additional
leukocytes [48,49], resulting in improved clearance of the
organism. Thus, lack of these protective proinflammatory
responses at baseline may be associated with subsequent IRIS.
In summary, a predisposition to developing IRIS is associated with
a paucity of cytokines involved in antigen processing and
macrophage function, such as TNF-a, coupled with increased
generalized inflammation (e.g., increased CRP, IL-17), lack of
antigen recognition by CD4
+ T cells (e.g., decreased VEGF), and
inappropriate Th2 responses (e.g., increased IL-4) before ART.
Biomarkers on ART
In addition to identifying pre-ART predictors of CM-IRIS, we
performed a time-to-event analysis to identify additional predictors
of IRIS that evolved in patients while on ART. After ART
initiation, analysis of changes in biomarkers during all time points
through the first 24 wk of ART showed a significant divergence in
inflammatory profiles associated with immune reconstitution
between cases and controls that was evident in blood weeks
before IRIS events. Increasing levels of CRP, D-dimer, IL-1RA,
IL-6, IL-7, IL-13, or G-CSF following initiation of ART were
associated with increasing hazard of IRIS (each p#0.001)
(Table 3). The pattern of inflammation indicated increasing levels
of biomarkers of generalized inflammation such as CRP, IL-6, and
D-dimer; inappropriate Th2 responses characterized by elevated
IL-13 levels; and elevated levels of growth factors such as G-CSF
and the T cell growth and differentiation factor IL-7. The anti-
inflammatory mediator IL-1RA increased following ART initia-
tion and before IRIS. The clinical implication of these findings is
that these biomarkers could be used to indicate risk for CM-IRIS
before the development of IRIS events, providing an opportunity
for intervention before clinical deterioration occurs.
Biomarkers of Inflammation at IRIS Events
At time of cryptococcal IRIS, serum biomarkers of inflamma-
tion were elevated in almost all IRIS patients over those in time-
matched controls (Table 4). However, the pattern of inflammation
was heterogeneous with individual variation (Table S1). Early
IRIS events were associated with more systemic inflammation
than were events occurring after 24 wk. IL-6 was most frequently
elevated at time of IRIS events (median 5-fold increase compared
with time-matched control participants). CRP levels often
correlated with IL-6 levels, as CRP is stimulated by IL-6; and
CRP levels were most often increased at IRIS diagnosis compared
with levels pre-ART or pre-event (Figure 4; p,0.001). In
comparing IRIS events with CNS manifestations versus non-
CNS IRIS events, there were no statistical differences in any
biomarker (each p.0.1) with the possible exception of D-dimer
being more elevated in non-CNS events (median 3.68 versus
2.22 mg/ml, unadjusted p=0.031). Interestingly, the inflammatory
Figure 2. Cumulative survival in persons with prior cryptococ-
cal meningitis newly initiating HIV therapy in Uganda is
stratified by the occurrence of cryptococcal IRIS. IRIS was
associated with increased mortality (HR=2.4, 95% CI 1.1–5.3,
p=0.035). Included with the controls are three suspected, but
unproven cases of CM-IRIS, three unknown causes of death (two
suspected pulmonary emboli). Two deaths have been excluded of
persons with known virologic suppression with clinical IRIS who refused
lumbar punctures to exclude alternative etiologies of their deteriora-
tion, of which one of these deaths was attributed to suicide.
doi:10.1371/journal.pmed.1000384.g002
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culture-positive CM relapse. In the relapse cases, CRP was normal
(,8 mg/l), whereas CRP was elevated in 76% of participants with
cryptococcal IRIS. These results confirm that IRIS is associated
with elevations in markers of inflammation that are large enough
to be measured in the serum and can help distinguish patients with
CM-IRIS from those with CM relapse before culture results are
available.
Biomarkers Predictive of or Associated with Mortality
In addition to evaluating predictors of IRIS, we performed
analyses to determine if inflammatory profiles could predict death.
Table 2. Pre-ART serum biomarkers associated with subsequent paradoxical cryptococcal IRIS.
Biomarker
(pg/ml)
CM Control
Median (IQR)
CM-IRIS Case
Median (IQR)
Odds Ratio per
2-Fold Increase p-Value
TNF-a 73.9 (27.3–130) 31.3 (,1.5–75.0) 0.500 0.001
IL-4 2.8 (2.2–3.5) 3.3 (2.2–4.0) 2.865 0.001
IL-17 66.1 (27.5–125) 47.8 (14.6–131) 1.306 0.018
VEGF 82.7 (47.0–155) 77.3 (34.4–176) 0.688 0.016
G-CSF 25.0 (14.7–41.3) 27.7 (15.0–53.2) 0.742 0.025
GM-CSF 18.8 (4.0–41.4) 8.2 (,1–24.8) 0.913 0.34
CCL2 (MCP-1) 35.7 (9.4–68.8) 24.5 (6.2–84.5) 1.036 0.45
Biomarkers on the day of starting ART that are associated with prediction of subsequent risk of paradoxical CM-IRIS. Risk estimates are calculated by logistic regression
using penalty parameters specified by the Lasso method based on log2-transformed data [41]. Thus, the odds ratio is reflective of the increased risk per 2-fold increase in
the serum biomarker value, adjusting for the influence of each of the biomarkers. p-Values are calculated by a multivariate logistic regression.
doi:10.1371/journal.pmed.1000384.t002
Figure 3. Cumulative incidence of cryptococcal IRIS. The data are based on a weighed predictive biomarker score composed of pre-ART serum
levels of seven biomarkers—IL-4, IL-17, G-CSF, GM-CSF, CCL2 (MCP-1), TNF-a, and VEGF—calculated as follows. Probability of IRIS=1= 1 z e{z ðÞ ,
where:
z ~ 4:383 z 1:052 log2IL   4 ðÞ z 0:267 log2IL   17 ðÞ { 0:298 log2G   CSF ðÞ {
0:091 log2GM   CSF ðÞ z 0:036 log2CCL2 ðÞ { 0:693(log2TNF   a) { 0:374 log2VEGF ðÞ :
Probability risk is scored from 0 to 1.0 with the categorical classification being defined for low risk (0–0.40), moderate risk (0.41–0.60), and high risk
(0.61–1.0). The performance as quantified by the AUC is 0.82 for correct prediction (i.e. C-statistic).
doi:10.1371/journal.pmed.1000384.g003
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identified baseline pre-ART serum biomarkers that were associ-
ated with subsequent mortality on ART. The best fit model
consisted of: IL-17, GM-CSF, IL-8, CXCL10, TNF-a, VEGF,
and CRP .32 mg/l with an AUC of 0.84 for correct classification
with 78% sensitivity, 81% specificity, 60% positive predictive
value, and 91% negative predictive value. A more parsimonious
three-biomarker model of increasing IL-17 or CRP .32 mg/l,
and decreasing GM-CSF, predicted increasing mortality
(AUC=0.76). A weighted score based on these three biomarkers
was used to classify high- and low-risk mortality groups (Figure 5).
Persons scored as high risk had 69% mortality (i.e., 69% positive
predictive value) whereas those with low risk had 83% survival (i.e.
83% negative predictive value), demonstrating the potential
clinical utility of the tool to identify patients at increased and
decreased risk for death. CRP alone was also clinically useful for
predicting risk of death (Figure 5). Participants with a CRP
.32 mg/l had 8-fold higher odds of all-cause mortality compared
to those with CRP,32 mg/l (OR=8.3, 95% CI 2.7–25.6,
p,0.001). Using these biomarkers as clinical tools at the time of
ARV initiation could be useful to identify high-risk patients and to
monitor them for early therapeutic intervention.
We also performed analyses to determine if levels of biomarkers
at time of IRIS events were associated with mortality. Among
persons experiencing CM-IRIS, mortality after an IRIS event was
associated with increased IL-10 levels (OR=2.8 per 2-fold change,
95% CI 1.3–5.9, p=0.007) and decreased IL-17 levels (OR=0.59
per 2-fold change, 95% CI 0.40–0.86, p=0.006) at event
compared to persons with IRIS who survived.
Table 3. Time-to-event analysis of the hazard of CM-IRIS by
serum cytokine profile evolving during ART.
Biomarker
Hazard Ratio per
2-Fold Increase 95% CI p-Value
IL-6 1.591 1.347–1.879 ,0.0001
CRP 1.516 1.266–1.816 0.0001
IL-7 1.931 1.408–2.646 0.0004
D-dimer 2.074 1.441–2.986 0.0006
G-CSF 1.442 1.198–1.736 0.0006
IL-1RA 1.416 1.172–1.712 0.0013
IL-13 1.456 1.159–1.830 0.0047
IL-9 1.277 1.050–1.553 0.047
IL-4 1.735 1.065–2.827 0.078
VEGF 1.233 1.011–1.505 0.097
IL-2 1.145 0.970–1.353 0.22
IL-17 1.031 0.911–1.167 0.80
IFN-c 1.107 0.824–1.486 0.69
TNF-a 1.012 0.876–1.170 0.90
The model incorporated the change from baseline in biomarkers over the first
26 wk of ART as time-dependent variables. p-Values are adjusted for multiple
comparisons via Benjamini-Hochberg correction [39]. The hazard ratio implies
that, as the biomarker increases, the relative risk of having an IRIS event
increases. See Table S2 for provision of all biomarkers and unadjusted p-values.
doi:10.1371/journal.pmed.1000384.t003
Table 4. Increase in serum biomarkers at the time of first IRIS event compared to time-matched controls.
Biomarker (pg/ml)
Controls Time-
Matched Median
IRIS Event (n=43)
Median
Geometric Relative
Increase
a 95% CI p-Value
CD4 (cells/ml) 44 (28–82) 77 (30.5–175) 0.077
CRP (mg/l) 8.2 (4.3–18.7) 39.5 (8.4–136) 298% 174%–422% 0.0004
IL-6 9.9 (4.7–22.1) 47.6 (20.7–129.2) 72% 52%–92% ,0.0001
IL-9 30.4 (9.6–51.8) 76.3 (28.7–115) 49% 26%–72% 0.0003
FGF-2 ,0.7 (,0.7–1.0) 17.3 (,0.7–72.7) 808% 537%–1080% 0.0004
G-CSF 23.5 (13.9–47.2) 52.2 (26.3–96.6) 19% 9%–29% 0.0005
GM-CSF 3.4 (,1.5–22.7) 21.7 (,1.5–65.5) 111% 61%–160% 0.0009
VEGF 92 (46–170) 203 (108–288) 22% 10%–34% 0.001
D-dimer (mg/ml) 1.6 (1.1–3.1) 3.1 (1.6–4.0) 50% 19%– 81% 0.003
IL-7 12.3 (8.1–20.7) 18.0 (12.8–35.3) 72% 52%–92% 0.003
IL-1RA 109 (50–204) 206 (100–368) 24% 10%–37% 0.005
IL-8 18.2 (9.9–31.9) 32.1 (17.0–62.7) 24% 11%–38% 0.006
IFN-c 116 (68–175) 167 (103–321) 12% 4%–20% 0.009
IL-17 65.2 (15.1–115) 109.9 (40.6–318) 19% 27% to 44% 0.018
IL-2 1.2 (,1– 6.8) 4.6 (,1–9.3) 154% 54%–255% 0.042
IL-10 9.5 (4.9–18.1) 13.6 (6.1–32.2) 37% 16%–58% 0.053
TNF-a 41.6 (14.1–103) 73.8 (13.9–111) 12% 27% to 30% 0.27
The table displays serum cytokines (pg/ml) at time of IRIS event compared to 2:1 cohort time match controls (n=86) from weeks 4 to 12 of ART, corresponding to the
approximate interquartile range of the timing of IRIS events. Statistical comparison is via Mann Whitney U nonparametric with Benjamini-Hochberg adjustment for
multiple comparisons [39], except for CD4, which is not adjusted.
aRelative increase is calculated per the relative risk reduction formula = (case – control)/control using the geometric mean of log2 transformed cytokines values.
doi:10.1371/journal.pmed.1000384.t004
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In this prospective cohort study of patients with AIDS and
recent CM in Uganda, we characterized the incidence and clinical
features of CM-IRIS and identified serum biomarkers that can
diagnose IRIS and can stratify the risk for IRIS or death. CM-
IRIS is a common complication of ART in sub-Saharan Africa,
with an incidence reported in the literature ranging from 10% to
31% [11,14–18,50]. In our cohort with ,1% loss to follow up, the
incidence of CM-IRIS was 45%, two-thirds of whom experienced
characteristic CNS manifestations (30%). Unlike many other
forms of IRIS, which produce less dramatic consequences, CM-
IRIS is exceptional for its substantial morbidity and mortality
[11,50–52]. The 36% CM-IRIS mortality in our study is
consistent with other CM-IRIS studies [14,15,17,18,52,53]. Such
dire outcomes may derive from the increased inflammation that
accompanies CM-IRIS in the anatomically constrained compart-
ment of the CNS.
Before this study, it was not possible to predict risk for CM-
IRIS. Epidemiologic factors, that were identified in retrospective
studies, were not predictive of CM-IRIS in our study, and have
not been found consistently across other studies [14,15,17,52].
Similar to a recent ACTG (AIDS Clinical Trial Group) a5164
trial, in our study timing of ART initiation was not associated with
IRIS [54]. In contrast, however, we identified specific patterns of
biomarkers that were predictive of the development of IRIS and
death at initiation of ART, after initiation of ART, and at IRIS
event.
Based on our identification of biomarkers that predict CM-
IRIS, our theoretical model is one whereby persons predisposed to
IRIS have more dysfunctional immune systems that fail to
effectively clear antigens from cryptococcus before ART-associat-
ed immune restoration. Indeed, persons with IRIS had higher
median serum CRAG titers when initiating ART than controls
without IRIS (p=0.006), but they had identical 1:1024 median
CSF CRAG titers at their initial CM diagnosis [46]. This result
may have implications for customization of timing of ART based
on initial induction antifungal therapy prescribed with a longer
delay required for less active antifungal therapy (e.g., fluconazole
monotherapy).
Further failures of antigen clearance may result from an
imbalance in immune regulation, initially characterized by
increased production of Th2 cytokines (IL-4, IL-13) and a lack
of the proinflammatory mediators (VEGF, TNF-a, G-CSF, GM-
CSF) that are required to recruit lymphocytes and activate
macrophages and other innate cells to clear C. neoformans.
Specifically, in neutrophils and macrophages, G-CSF and GM-
CSF promote phagocytosis, up-regulation of reactive oxygen
species, and intracellular destruction of cryptococcus [33–36].
Decreased pre-ART levels of G-CSF, GM-CSF, and TNF-a
should result in decreased phagocytosis and promotion of a fertile
intracellular environment within macrophages for cryptococcus
[36,49]. Based on our model of CM-IRIS pathogenesis, this
inappropriate or ineffective macrophage activation leads to failure
to clear cryptococcal organisms and predisposes toward the
development of CM-IRIS. In this respect, CM-IRIS pathogenesis
may parallel the proposed mechanism of TB-IRIS [55].
A failure of antigen clearance promotes generalized inflamma-
tory signaling to then occur, specifically with IL-6. Compared with
time-matched control participants, persons who developed IRIS
had elevated levels of CRP before ART initiation, and elevated
levels of CRP and IL-6 before and at the time of IRIS events. Our
results indicate that the inflammatory signaling response involving
IL-6 progressively increased on ART until the development of
IRIS. Since IL-6 is the primary stimulant of hepatic CRP
production, it is unsurprising that these biomarkers had similar
patterns. French and colleagues reported similar increases in
plasma IL-6 after a variety of IRIS events or before herpesvirus-
related IRIS events, and they verified by flow cytometry
experiments that activated macrophages were the primary source
of IL-6 [56,57].
We hypothesize that the abnormal cytokine profiles we observed
before CM-IRIS, including elevations of Th2 cytokine (e.g., IL-4,
IL-13) and lack of proinflammatory cytokines such as TNF-a,
indicate ineffective or inappropriate alternative macrophage
activation. In contrast to Th1 responses, which promote IFN-c–
mediated killing of cryptococcus by macrophages [28,32], IL-4
produced in Th2 cells causes alternative activation of macrophag-
es—typically a response to parasite infections—promoting fibrosis
[58]. Alternative activation of macrophages allows for intracellular
Figure 4. Individual longitudinal increases in CRP and IL-6 from baseline pre-ART, to the time point before IRIS, and at time of IRIS
event. The gray shading represents the interquartile range (25
th to 75
th percentile) of the CM cohort controls without IRIS over the first 8 wk of ART.
The median time of IRIS was 8.8 wk. IL-6 and CRP are increased before the IRIS event (p,0.001) and at time of IRIS (p,0.001).
doi:10.1371/journal.pmed.1000384.g004
Biomarkers of Cryptococcal IRIS
PLoS Medicine | www.plosmedicine.org 8 December 2010 | Volume 7 | Issue 12 | e1000384growth, proliferation, and dissemination of C. neoformans [28,29].
In other fungal processes, IL-4 reverses GM-CSF–mediated
macrophage killing of yeast in vitro [59]. In our results, small
quantitative increases in IL-4 were associated with large statistical
increases in IRIS risk. Since Th1 and Th2 responses are often
mutually exclusive, inappropriate increases in Th2 responses (e.g.,
IL-4, IL-10, IL-13) generate ineffective inflammation and inhibit
the protective Th1 responses necessary for efficient antigen
clearance. The association of a Th2 bias and risk for IRIS was
evident with elevated IL-4 levels at baseline, elevated IL-13 levels
on ART before IRIS events, and elevated IL-10 levels at IRIS
events as well as an association between increased IL-10 levels at
IRIS and subsequent death. The Th2 responses that limit
clearance of C. neoformans may be driven by preexisting Th2 biases
to other concomitant coinfections, such as intestinal helminths or
schistosomiasis. This phenomenon might underlie the higher
overall incidence of IRIS in our cohort compared to cohorts from
temperate regions [14,15,17,50]. Unexplained absolute eosino-
philia (.500 cells/ml) was present in over one-quarter of the
cohort; however there were not statistical differences in eosinophils
or total serum IgE between cases and controls. Overall, our data
suggest that Th2 responses to cryptococcus are associated with
poor outcomes, including increased risk for IRIS and death.
Risk factors for IRIS extend beyond the Th1:Th2 paradigm.
Increased Th17 responses (i.e. IL-17) were a pre-ART risk for
both IRIS and mortality on ART. Proinflammatory Th17 cells
have been previously hypothesized as important in IRIS
pathogenesis [60,61]. In normal immune homeostasis, a balance
between Th17 cells and regulatory T cells (Treg) is crucial. A
Th17 imbalance can cause autoimmune diseases. In this balance,
IL-6 plays a key role in naı ¨ve T cell differentiation inducing Th17
differentiation and inhibiting Treg differentiation in the presence
of TGF-b [62]. The copious IL-6 present before IRIS events may
alter the balance between Treg and Th17 cells, suppressing Treg
differentiation or function during ART-related immune reconsti-
tution.
Additionally, other cytokines that we identified may play a role
in IRIS pathogenesis by contributing to ineffective macrophage
activation. For example, low pre-ART levels of TNF-a or VEGF
were associated with increased IRIS risk. TNF-a, secreted by
macrophages and T cells, is particularly important in activating
antigen-presenting cells. Absence of TNF-a causes failure of
mature dendritic cell activation and recruitment, thereby blunting
further recruitment of T cells [63]. Lack of TNF-a could indicate
failure to present and/or process antigen and could contribute to
ineffective macrophage activation in patients at risk for IRIS. In
cryptococcosis, VEGF is secreted by a variety of leukocytes but
especially by CD4
+ T cells during antigen-specific responses to
cryptococcal mannoprotein being presented by MHC-II molecules
[64]. Decreased VEGF may reflect greater immune dysfunction
due to failure of CD4
+ T cell antigen recognition from antigen-
presenting cells. The downstream effects of decreased VEGF
would further diminish both chemotaxis and the costimulatory
activity of VEGF on IFN-c–secreting Th1 memory T cells [65].
Thus, decreased VEGF may then diminish the Th1 response and
shift the Th1:Th2 balance toward Th2 responses. The decreased
levels of TNF-a and VEGF in patients at risk for IRIS may be
causes or reflections of impaired macrophage function. Overall,
the inappropriate Th2 responses and IL-4 production, coupled
with ineffective macrophage activation, suggest that a failure in
pathogen recognition and clearance could set the stage for
paradoxical IRIS by promoting antigen persistence. Upon
eventual immune restoration of more appropriate antigen-specific
responses, these responses are exaggerated because of the
Figure 5. Survival on ART in persons with prior cryptococcosis
stratified by their mortality biomarker risk score. (A) Full
predictive model (AUC=0.84). (B) Parsimonious three-biomarker model
based on IL-17 (p=0.015), GM-CSF (p=0.022), and categorical CRP
.32 mg/l (p=0.004) (AUC=0.76). With a categorical cutoff point for
the model with high risk of probability .0.5 to 1.0, the positive
predictive value was 69% and negative predictive value 83% with 48%
sensitivity and 92% specificity. (C) Survival stratified by baseline, pre-
ART CRP level of,32 or $32 mg/l (AUC=0.65). The three respective
ROC curves are presented in Figure S4.
doi:10.1371/journal.pmed.1000384.g005
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a proinflammatory state.
Study Strengths
Strengths of this study include its prospective design, careful and
complete follow-up, and integration of pathophysiologic analyses
in the context of characterizing clinical phenotypes. As such, we
believe the results reported here are generalizable to cryptococcal
IRIS as a pathophysiologic entity. In general, the diagnoses of
other forms of IRIS are somewhat subjective, but in CM-IRIS, the
identification of IRIS in the CNS is very objective due to the
ability to examine the CSF, where the inflammation occurs. A
problem arises with non-CNS manifestations of IRIS, which often
represent diagnoses of exclusion and depend on the diagnostic
capabilities available. In this cohort, we identified several (n=20)
non-CNS IRIS events, of which 60% were associated with later
CNS-IRIS events or with supportive/definitive histopathology
(Text S1). Eight cases (retinitis, optic neuritis, keratoconjunctivitis,
pneumonitis; n=5) were probable IRIS diagnoses and unsupport-
ed by histopathology or culture (17% of total IRIS cases).
Although cryptococcus most often causes meningitis, cryptococ-
cosis is a disseminated disease with systemic CRAG measurable for
months in peripheral blood [66]. In our experience here, dead C.
neoformans causing IRIS reactions were identified in tissue by
histopathology of brain, lymphatics, gut, skin, and tongue and
were isolated via bronchoalveolar lavage. Thus, non-CNS
cryptococcal IRIS events do occur, allowing these ‘‘probable
events’’ as likely, but not definitely, attributable to IRIS. In
separately considering these non-CNS IRIS events, there were no
statistical differences in the inflammatory profiles observed at time
of IRIS as compared to CNS-IRIS events, except for possibly D-
dimer. In Uganda, there is likely high and ongoing environmental
exposure to cryptococcus [1,4], thus pneumonitis-IRIS could
equally be triggered by persisting original antigen or by
environmental re-exposure manifesting effectively as an acute
hypersensitivity pneumonitis reaction. Pulmonary cryptococcosis
often goes unrecognized and/or is suspected as smear-negative TB
[67].
Study Limitations
This prospective observational study has allowed us to
characterize the statistical association between cytokine profiles
and IRIS. Of course, this does not prove causality; however, the
anomalies we report are biologically plausible within the known
immunology of responses to cryptococcus. A challenge in
pathogenesis studies such as ours is that the inflammatory
profiles associated with IRIS are heterogeneous, representing a
continuum that is likely dependent on the duration of symptoms,
the antigen, and the robustness of the event. In cytokine
profiling, six of our participants had minimal immunologic
perturbation in peripheral blood even though they clinically
deteriorated, presenting with headache and elevated intracranial
pressure several months into ART. Thus, some patients fulfilling
the IRIS clinical case definition either have localized immune
responses that were not detectable in peripheral blood, or they
may not have had true immunologic IRIS but instead had
delayed complications of CM that were clinically indistinguish-
able from CM-IRIS. This heterogeneity may have implications
for IRIS management and the response to anti-inflammatory
therapies. Although this prospective study of CM-IRIS is the
largest to date, our biomarker data should be viewed as
hypothesis-generating and will require validation in future
cohorts. We plan to validate these biomarkers in subjects
enrolled in the multi-site Cryptococcal Optimal ART Timing
(COAT) trial (NCT 01075152; http://clinicaltrials.gov/ct2/
show/NCT01075152) and investigate these biomarkers with
regard to timing of ART initiation after CM diagnosis. This
validation will give insight on whether altering the timing of ART
initiation is a potential intervention to alter high risk or whether
other strategies should be pursued. Once validated, creating
diagnostics such as multiplex ELISAs or bead-based techniques
could move this into clinical use.
Conclusions
Given the high incidence, morbidity, and mortality associated
with CM-IRIS, identifying patients at risk for IRIS may enable
interventions to improve management. Three distinct phases of
IRIS pathogenesis can be identified (Table 5). First, before ART,
a paucity of innate inflammatory responses or inappropriate
(Th2) responses promote ineffective antigen clearance. Second,
after ART initiation, copious antigen presentation promotes
proinflammatory signaling (e.g., IL-6, CRP, IL-7). Third, at the
time of IRIS, a generalized cytokine storm occurs. The
biomarkers identified here, although requiring validation, may
Table 5. Summary of paradoxical cryptococcal-IRIS pathogenesis hypothesis.
Phase Immunologic Activity Evidence in CM-IRIS Patients
Before ART N Paucity of appropriate inflammation for
cryptococcosis and/or
N Q TNF-a, G-CSF, GM-CSF, VEGF in serum
Q IFN-c, G-CSF, TNF-a, IL-6 in CSF [46]
N Inappropriate (Th2) responses resulting in: N qIL-4 pre-ART
N Poor antigen clearance, pre-ART N Similar CSF CRAG at initial infection [46]
Higher CRAG pre-ART
After starting ART N Increasing proinflammatory signaling from APCs due to
persisting antigen burden and failure to clear antigen
N q IL6 from macrophages [56] then downstream
q CRP production; q IL-7 from APCs
N Secondary activation of coagulation cascade N q D-dimer
At IRIS N Cytokine storm of multiple immune pathways of innate
and adaptive immune systems
N Th1 q INF-c, VEGF; TH17 q IL-17
Innate: q IL-8, G-CSF, GM-CSF
N Activation of coagulation cascade N q D-dimer
N Neuronal cell activation and damage N q FGF-2
doi:10.1371/journal.pmed.1000384.t005
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adjunctive GM-CSF or IFN-c to increase macrophage function,
(2) antiparasitic therapy to eliminate coinfections that promote
inappropriate Th2 bias, (3) anti-IL-6 receptor antibody (tocili-
zumab) therapy to blunt inflammatory signaling, or (4) delaying
ART initiation. This study suggests that prediction of IRIS or
death may be possible with measurement of pre-ART serum
biomarkers.
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3668 y. The baseline median CD4
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44–115) cells/ml, p,0.001) with a gradual increase thereafter to a
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calculated as follows:
8-cytokine model : z ~ 5:91 z 1:50 log2IL-4 ðÞ
{ 0:03 log2IL-12 ðÞ z 0:34 log2IL-17 ðÞ
{ 0:46 log2G-CSF ðÞ { 0:12 log2GM-CSF ðÞ
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5-cytokine model : z ~ 1:62 z 0:13 log2IL-4 ðÞ
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Background. Since 1981, AIDS has killed more than 25
million people and about 33 million people are now infected
with HIV, which causes AIDS. HIV, which is most often
transmitted through unprotected sex with an HIV-infected
partner, infects and kills immune system cells. Eventually, the
immune system becomes so weak that unusual infections
begin to occur. These ‘‘opportunistic’’ infections are
infections that take advantage of the opportunity offered
by a weakened immune system. One common and deadly
opportunistic infection in people affected by AIDS is
cryptococcal meningitis (CM), an infection around the brain
that is caused by the fungus Cryptococcus neoformans. About
one million cases of CM occur every year. CM can be treated
with a drug called amphotericin but usually recurs unless
another drug called fluconazole is taken daily thereafter. HIV
therapy is lifesaving by suppressing the HIV virus and
allowing immune system recovery. This immune recovery
also helps to prevent the recurrence of CM.
Why Was This Study Done? Unfortunately, HIV therapy
can also elicit a serious condition called immune
reconstitution inflammatory syndrome (IRIS) in people with
CM and AIDS. IRIS is an exaggerated inflammatory immune
response that kills up to one-third of affected people.
Inflammation, which is characterized by swelling and
redness, is the body’s first defense against infection, but
uncontrolled inflammation causes widespread tissue
damage. Experts think that CM-IRIS may be the result of an
unbalanced recovery of the immune system leading to an
inappropriate immune response to persisting C. neoformans
fragments and proteins that are slowly cleared from the
body over months. Unfortunately, it is impossible to predict
which individuals with CM and AIDS will develop IRIS when
they are given HIV therapy. In this prospective study, the
researchers investigated clinical features and cytokine
profiles in a group of Ugandans with AIDS and recent CM
for one year after starting HIV therapy to identify biomarkers
that could be used to predict and diagnose CM-IRIS.
Cytokines are proteins secreted by immune system cells
that regulate the immune response; biomarkers are proteins
found in the blood that indicate specific diseases.
What Did the Researchers Do and Find? The researchers
enrolled 101 Ugandans with AIDS and recent CM who had
not previously received HIV therapy. They compared
cytokine patterns in individuals who did and did not
subsequently develop IRIS after starting HIV therapy.
Overall, 45% of the patients developed IRIS. Deaths
occurred in 36% of the patients who developed IRIS and in
21% of those who did not develop IRIS. Patients who
developed CM-IRIS after starting HIV therapy had 4-fold
higher baseline concentrations of cryptococcal antigen in
their blood than patients who did not develop CM-IRIS. Prior
to starting HIV therapy, higher levels of the cytokines IL-4
and IL-17 and lower levels of four cytokines—TNF-a, G-CSF,
GM-CSF, and VEGF—predicted IRIS development, and an
algorithm (formula) based on the baseline levels of seven
serum biomarkers was able to group the patients into high,
moderate, and low risk of IRIS. After starting HIV therapy,
increasing levels of the inflammatory proteins C-reactive
protein and D-dimer, and of several cytokines, were
associated with an increased risk of IRIS. At the time of IRIS
onset, the levels of many proinflammatory cytokine
increased. Biomarkers also predicted death after starting
HIV therapy with increasing levels of IL-17, decreasing levels
of GM-CSF, and a C-reactive protein level of more than
32 mg/l (four times higher than normal) predicted death
within one year.
What Do These Findings Mean? These findings support
the hypothesis that some AIDS patients who have a very
damaged immune system have a very poor initial immune
response and poor clearance of cryptococcus, which
predisposes them to IRIS. The findings also identify three
distinct phases of IRIS development. Before HIV therapy, a
very damaged immune system with a lack of inflammatory
responses to infection or inappropriate responses leads to
ineffective clearance of the organism and its antigens. After
HIV therapy is started, the presence of copious antigens
promotes proinflammatory signaling to the immune system.
As the immune system recovers proinflammatory immune
cells are promoted. Finally, at the time of IRIS, a generalized
‘‘cytokine storm’’ occurs, which is potentially fatal when this
inflammation occurs in the brain. The biomarkers identified
here as indicators of a predisposition to IRIS need to be
validated in more patients in more countries before they can
be used as a clinical tool for predicting the risk of IRIS. If they
are validated, they could help clinicians decide when to start
HIV therapy in patients with AIDS and recent CM, and could
guide the use of therapies that could help prevent the
abnormal inflammatory responses.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000384.
N The US National Institute of Allergy and Infectious Diseases
provides information on HIV infection and AIDS
N HIV InSite has information on all aspects of HIV/AIDS,
including Knowledge Base Chapters on cryptococcosis and
HIV and on the clinical implications of IRIS
N Information is available from Avert, an international AIDS
charity on all aspects of HIV/AIDS, including HIV-related
opportunistic infections (in English and Spanish)
N The MedlinePlus encyclopedia has a page on cryptococcal
meningitis (in English and Spanish)
N AIDS InfoNet provides fact sheets on many HIV/AIDS
topics, including a fact sheet on cryptococcal meningitis (in
several languages) and treatment guidelines for opportu-
nistic infections
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